Icahn Institute for Data Science and Genomic Technology

KoverNow Appoints one of Singapore’s Most Prominent Marketing and Data Science Experts as Non-Executive Director

Retrieved on: 
Tuesday, January 31, 2023
Trust, AI, Assistant, Sungkyunkwan University, National University of Singapore, Theory, Data science, Economics, Big data, Intelligence, Behavioral economics, Senior, Icahn Institute for Data Science and Genomic Technology, National university, Associate, NUS, Research, Management, Marketing

Professor Chong, who is a behavioral scientist and data scientist by training, currently carries out research focusing on the challenges of nudging people to adopt useful technology.

Key Points: 
  • Professor Chong, who is a behavioral scientist and data scientist by training, currently carries out research focusing on the challenges of nudging people to adopt useful technology.
  • He joins KoverNow as a non-executive director.
  • Professor Chong’s expertise is in using behavioral and economic principles and data analytics and AI tools.
  • Stephan Kaiser, CEO at KoverNow, said: “Professor Chong has a rich history of advising start-ups in the application of big data and artificial intelligence to their marketing strategies.

CDISC Welcomes New Chair and Members to Board of Directors

Retrieved on: 
Tuesday, January 10, 2023
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, FDA, Clinical Trials, ICON, Roche, Bristol Myers Squibb, University, Veeva Systems, Eli Lilly, New product development, Icahn Institute for Data Science and Genomic Technology, All, Daiichi Sankyo, Novo Nordisk, EDC, SAS Institute Inc v World Programming Ltd, AbbVie, Population health, Pharmaceutical industry, Management, Medical device, CDISC

CDISC today announced three members have joined its Board of Directors: Jonathan Chainey, Dominic Labriola and Rhona O’Donnell each began serving a three-year term at the beginning of the year.

Key Points: 
  • CDISC today announced three members have joined its Board of Directors: Jonathan Chainey, Dominic Labriola and Rhona O’Donnell each began serving a three-year term at the beginning of the year.
  • Prior to his election to the CDISC Board of Directors, Jonathan served as chair of the CDISC Advisory Council .
  • “We enthusiastically welcome these new board members,” said Erik Pulkstenis, CDISC board Chair.
  • For more information on the CDISC Board of Directors, please visit www.cdisc.org/about/board .

ConcertAI Presentation at JP Morgan Healthcare Conference Outlines Key Advances in DaaS and AI SaaS Research Platforms for Translational Sciences and Clinical Development

Retrieved on: 
Tuesday, January 10, 2023
Cancer, EBITDA, WES, Sequence, Medicine, American Society of Clinical Oncology, Investment, Caris, RWE, Doctor of Philosophy, Standard of care, JPM, SDV, MS, Research, Social determinants of health, Intelligence cycle, Excellent, Publication, TMB, BMS, FDA, Software as a service, Deletion, Partnership, National Center for Advancing Translational Sciences, RWD, Data as a service, Gold, Icahn Institute for Data Science and Genomic Technology, MSI, AI, GLOH, DACT, Therapy, Health Resources and Services Administration, Senior, Society, Collection, Natural language, Phase II, HRD, NLP, MBA, R, Natural language processing, Patient, Bristol Myers Squibb, Conference, Clinical data management system, Pharmaceutical industry, Management, Medical imaging, Health equity

CAMBRIDGE, Mass., Jan. 10, 2023 /PRNewswire/ -- ConcertAI, LLC ( ConcertAI ), a leader in AI Software-as-a-Service (SaaS) technology and Real-world Evidence (RWE) solutions for life sciences and healthcare, presented at the JP Morgan Healthcare Conference (JPM) today.

Key Points: 
  • CAMBRIDGE, Mass., Jan. 10, 2023 /PRNewswire/ -- ConcertAI, LLC ( ConcertAI ), a leader in AI Software-as-a-Service (SaaS) technology and Real-world Evidence (RWE) solutions for life sciences and healthcare, presented at the JP Morgan Healthcare Conference (JPM) today.
  • In late 2022, ConcertAI and Caris Life Sciences launched a broadscale reference platform for Translational Sciences, announced publicly on January 9, 2023.
  • The collaboration creates the leading and most comprehensive oncology translational and clinical development multi-modal research data platform aimed at supporting and accelerating biopharmaceutical drug development and novel therapeutic research.
  • This leadership teams' experience and depth of expertise in research, services, and oncology technologies is unprecedented in the industry."

NCKU Researchers Demonstrate Machine-learning Assisted Detection of Age-related Macular Degeneration from Fundus Photos

Retrieved on: 
Monday, January 9, 2023
Data science, ML, Architecture, Automatic, NCKU, Severe cognitive impairment, Medical imaging, Classification, ResNet, AMD, Fundus, Data, Machine learning, U-Net, Icahn Institute for Data Science and Genomic Technology, Hospital, National Cheng Kung University, ADAM, IEEE Engineering in Medicine and Biology Society, Diagnosis, Retina, Computer data storage, Medical device

Fundus photography is a powerful tool that can be used to detect AMD; however, it is time-consuming and requires the expertise of a medical professional.

Key Points: 
  • Fundus photography is a powerful tool that can be used to detect AMD; however, it is time-consuming and requires the expertise of a medical professional.
  • To this end, the Automatic Detection challenge on Age-related Macular degeneration or the ADAM challenge was set up as a satellite event of the ISBI 2020 conference.
  • The team from NCKU used four different ML architectures to address each task of the ADAM challenge.
  • The team used a multiple-blocks regression strategy to divide the fundus image into multiple blocks, after which each block was one-hot-encoded.

Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Thursday, December 1, 2022
IND, Prostate cancer, Chronic lymphocytic leukemia, Lymphatic system, Docetaxel, Employment, Head, Icahn Institute for Data Science and Genomic Technology, Cancer, Castration, Biometrics, CD19, ROR1, MCL, Patient, CAR, Venetoclax, MCRPC, Drug development, SAN, CLL, Pharmaceutical industry

The award was made on December 1, 2022 under Oncternals 2021 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of Oncternal as an inducement to join the Company.

Key Points: 
  • The award was made on December 1, 2022 under Oncternals 2021 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of Oncternal as an inducement to join the Company.
  • The award consists of an option to purchase 77,400 shares of Oncternal common stock.
  • The option has a 10-year term and an exercise price equal to the closing price of Oncternals common stock on the date of grant.
  • The award was approved by Oncternals compensation committee, comprised entirely of independent directors, as required by Nasdaq Rule 5635(c)(4), and was granted as an inducement material to the employee entering into employment with Oncternal in accordance with Nasdaq Rule 5635(c)(4).

Bristol Myers Squibb and ConcertAI Advance Novel Oncology Accelerated Digital Clinical Trial Solution

Retrieved on: 
Thursday, September 29, 2022
Real-World Evidence, RWE, Time, Real world evidence, Digital technology, COVID-19, Hematology, Icahn Institute for Data Science and Genomic Technology, LLC, Health, DACT, Partnership, Industry, Gold, Patient, Clinical trial, The Society for Basic Urologic Research, Cancer, Data collection, Technology, Solution, Doctor of Philosophy, Research, BMS, R, IRB, Bristol Myers Squibb, AI, Software as a service, Medical imaging, Pharmaceutical industry

CAMBRIDGE, Mass., Sept. 29, 2022 /PRNewswire/ -- ConcertAI, LLC (ConcertAI) announced the launch of its new Digital Trial Software-as-a-Service solution. Powered by ConcertAI's deep and broad real-world data, IT infrastructure, digital technology and a broad network of leading research sites, Digital Trial Solution integrates clinical research and clinical practice seeking to simplify patient identification, consent, IRB approval and contract negotiations. This offering seeks to ultimately reduce or eliminate duplicative data entry and constant data monitoring so clinical research staff can focus their resources on patient care.

Key Points: 
  • The first Fully Digital, Clinical Trial Solution for Oncology, Hematology & Urology
    CAMBRIDGE, Mass., Sept. 29, 2022 /PRNewswire/ -- ConcertAI, LLC (ConcertAI)announced the launch of its new Digital Trial Software-as-a-Service solution.
  • Powered by ConcertAI's deep and broad real-world data, IT infrastructure, digital technology and a broad network of leading research sites, Digital Trial Solution integrates clinical research and clinical practice seeking to simplify patient identification, consent, IRB approval and contract negotiations.
  • "The Digital Trial Solution will allow us to accelerate access to innovative, lifesaving cancer medicines to patients.
  • "We are extremely proud to have worked with ConcertAI for the past two years to help them shape this highly innovative digital solution," said Marisa Co, vice president, R&D Business Insights & Analytics, Bristol Myers Squibb.

BioDatAi and Self Pay Medical Partner to Provide Consumers the Power to Make Educated Medical Purchasing Decisions

Retrieved on: 
Saturday, June 11, 2022
Data, Intelligence, Telehealth, LLC, Icahn Institute for Data Science and Genomic Technology, Health care, CEO, Interoperability, ETT, AI, Partnership, Solution, Hospital, Compliance, Machine learning, Adviser, Industry, Health, Integration, Platform as a service, Health insurance

FRISCO, Texas, June 10, 2022 /PRNewswire-PRWeb/ -- BioDatAi, the healthcare subsidiary of Dallas-based Economic Transformation Technologies (ETT), an accelerator and integrator of innovative technologies, announced it has launched its Intelligent Interoperability Platform (PaaS) and a new strategic partnership with Self Pay Medical to provide a platform for healthcare price transparency that is intuitive for the consumer to use and easy for healthcare providers to openly share pricing for their services.

Key Points: 
  • "Unlike most markets, healthcare has not been transparent with consumer price prior to services being rendered.
  • As many Americans are funding healthcare out of their own pocket, they deserve to have price transparency," added Cook.
  • "The partnership between Self Pay Medical and BioDatAi will enable us to effectively capture and curate price data through the utilization of our Healthcare Intelligent Interoperability Platform and provide consumers with information they need to make educated medical purchasing decisions."
  • Over the last five years, Self Pay Medical has been determined to put the power back in the hands of the consumer by providing easy access to medical pricing at the provider level.

Bruker Appoints Philip Ma to its Board of Directors

Retrieved on: 
Wednesday, March 16, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Frank Laukien, SEC, Form 10-Q, Annual report, Partnership, Proteomics, Solution, Risk, Board of directors, Microscopy, McKinsey & Company, Multimedia, Nasdaq, Organic acid, Biochemistry, Massachusetts Institute of Technology, Biogen, University of Oxford, Molecular biology, Systems biology, Economics, Life, Founder, Icahn Institute for Data Science and Genomic Technology, Security (finance), Form 10-K, Protein, Board, Goal, Company, Research, Cancer, CEO, Cell biology, Securities Exchange Act of 1934, Harvard University, U.S. Securities and Exchange Commission, Biology, Securities Act of 1933, Disease, Corporation, Management, Bruker, Philip

Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has appointed Philip Ma, Ph.D. to serve on its board, effective as of April 1, 2022.

Key Points: 
  • Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has appointed Philip Ma, Ph.D. to serve on its board, effective as of April 1, 2022.
  • Dr. Ma was a macromolecular crystallographer at the Massachusetts Institute of Technology, where he earned his Ph.D. in biology.
  • We are very pleased to welcome Philip to the Bruker board.
  • I look forward to working with Frank and the Bruker team to plan and work towards this exciting future, commented Dr. Ma.

Biomarker Discovery from Gene Expression: Challenges and Solutions for Success, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, February 2, 2022
Icahn Institute for Data Science and Genomic Technology, Diagnosis, Prognosis, VP, Food, Industry, Gene, Gene expression, Biomarker discovery, Success, Solution, Clinical trial, Medical device

However, this potential has yet to be fully realized despite the exponential increase in genomic data during this period.

Key Points: 
  • However, this potential has yet to be fully realized despite the exponential increase in genomic data during this period.
  • A strategic approach for biomarker discovery aligned with the development and validation path of the therapeutic is essential.
  • Almac Diagnostics Services has substantial expertise in biomarker discovery from gene expression, taking them beyond the proof-of-concept phase to analytically validate and deliver prospectively for clinical trial stratification.
  • For more information, or to register for this event, visit Biomarker Discovery from Gene Expression: Challenges and Solutions for Success.

Radboud University Medical Center Increases HiFi Sequencing Capacity with PacBio’s Sequel IIe

Retrieved on: 
Friday, January 7, 2022
Molecule, A-DNA, Family, Single-molecule real-time sequencing, Choroideremia, Icahn Institute for Data Science and Genomic Technology, Degenerative disease, Doctor of Philosophy, Growth, Research, Abraxis BioScience, Chronic lymphocytic leukemia, Patient, Biomedical Research, DNA, Pacific Biosciences, Cancer, Securities Exchange Act of 1934, WGS, U.S. Securities and Exchange Commission, Microbiology, Security (finance), Efficiency, Disease, NASDAQ, SMRT, Private Securities Litigation Reform Act, Genome, IGH, Royal commission, GLOBE, High fidelity, Technology, Associate, Lists of diseases, Genetic variation, European Commission, Medical imaging, Antibiotics, CLL, Radboud University Medical Center

MENLO PARK, Calif., Jan. 07, 2022 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB), a leading developer of high-quality, highly accurate sequencing platforms, today announced Radboud University Medical Center (Radboudumc) in Nijmegen, the Netherlands will increase their SMRT sequencing capacity with the addition of two new PacBio Sequel IIe Systems .

Key Points: 
  • MENLO PARK, Calif., Jan. 07, 2022 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB), a leading developer of high-quality, highly accurate sequencing platforms, today announced Radboud University Medical Center (Radboudumc) in Nijmegen, the Netherlands will increase their SMRT sequencing capacity with the addition of two new PacBio Sequel IIe Systems .
  • In addition, they use the Sequel system for mitochondrial DNA (mtDNA) sequencing because it is much more efficient.
  • Unexpected benefits were seen both in efficiency and sensitivity with small amplicon-based sequencing for IGH mutation analysis in CLL (chronic lymphocytic leukemia) cancer samples.
  • TheSequel IIe Systemgenerates HiFi sequencing reads, which provide the accuracy and completeness required for investigating DNA variation in rare genetic diseases and cancer.